A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
To demonstrate superiority of OXN PR compared to placebo with respect to analgesic efficacy
in subjects with chronic severe pain associated with Parkinson's disease (PD), as assessed by
averaged 24 hour pain scores collected for 7 days prior to the clinic visits